

LITERATURE REVIEW SARS-CoV 2 Clinical Presentation

By: Anisha Guda, Kavina Patel, Aleena Vargas, Tracey Vuong, Caroline Zhu, Taylor McCracken, Saima Yazji, Anusha Sherwani, Cynthia Jiang, Noah Hodson, Keerthana Nimmagadda, Keerthi Thallapareddy, and Ashley Andrew
Peer reviewed by: Dr. Philip Ponce, Dr. Kelly Echevarria

updated 03/08/2021



TYPICAL PRESENTATION

COMMON SYMPTOMS

Fever (70%)
Cough (70%)
Dyspnea (70%)
Muscle Aches (36%)
Headaches (34%)

Others: fatigue, anorexia, anosmia, dysgeusia, diarrhea, nausea / vomiting, abdominal pain, sputum production, hemoptysis, cutaneous manifestations

LABS

lymphopenia, hypoalbuminemia, elevated CRP, elevated LDH, elevated ESR, normal procalcitonin

IMAGING

Bilateral multi-focal opacities on CXR, bilateral ground glass opacities on CT
Chest ultrasound useful in detecting peripheral pulmonary pathologies and interstitial syndromes

KEY GROUPS FOR ATYPICAL PRESENTATION

IMMUNOCOMPROMISED

- *** **CANCER PATIENTS:** healthcare exposure is significant risk factor; breast & prostate cancer more prevalent among US & UK patients, with increased risk of severe outcomes, including intubation & death
- *** **ORGAN TRANSPLANTS:** significant proportion in US are Hispanic or African American; increased disease severity and mortality
- *** **HIV+ PATIENTS:** inconclusive data if higher risk of severe disease
- *** **ON LONG TERM GLUCOCORTICOIDS:** longer incubation and viral shedding periods shown in single familial cluster report

CHILDREN

Visit pediatric infographic

PREGNANT WOMEN

- Most are mild and often asymptomatic.
- Pregnant women with COVID-19 are more likely to be hospitalized and are at increased risk for ICU admission and receipt of mechanical ventilation than nonpregnant women.

ELDERLY

- Significantly higher rate of severe disease, ICU admission, and mortality than younger patients
- Non-specific signs & symptoms are falls, general health decline, delirium, and GI symptoms
- Can be asymptomatic

INCUBATION PERIOD

14 days from time of exposure
4 to 5 days median incubation period

DURATION OF ILLNESS

Mild to moderate disease: 2 weeks
Severe disease: 3-6 weeks

ASYMPTOMATIC PRESENTATION

*** **40-45%** of those infected with SARS-CoV-2 will remain asymptomatic for duration of illness
May be associated with CT abnormalities


DISEASE SEVERITY

Among 72,314 persons with COVID-19 in China.

Mild: no or mild pneumonia

Severe: dyspnea, respiratory distress

Critical: respiratory failure, septic shock, and/or multi-organ dysfunction or failure



SEVERE DISEASE AND MORTALITY

RISK FACTORS FOR SEVERE DISEASE AND MORTALITY

- Non-Modifiable**
 - Older age (>65 years)
 - ***Black, Hispanic, or South Asian ethnicity
 - Male sex
 - In patients age >60 years: muscle aches, absence of fever
 - Cancer patients - highest fatality rates seen with hematologic and lung malignancies, and in age groups 45-60 years and >75 years.
 - High SOFA score
 - Down Syndrome
- Modifiable**
 - Hypertension, cardiovascular disease, cerebrovascular disease
 - Overweight (BMI 25 - <30), obesity (BMI ≥ 30 kg/m²), diabetes mellitus
 - Smoking history (current>former), COPD
 - High-dose corticosteroid use
 - Acute kidney injury (AKI) during hospitalization

PROGNOSTIC MARKERS OF SEVERE DISEASE

- Hematologic**
 - Thrombocytopenia, lymphopenia
 - Elevated RDW (>14.5%) at admission and increasing RDW during hospitalization
 - High neutrophil:lymphocyte ratio (especially in males)
 - Significantly elevated WBC count (WMD: 4.15x10⁹/L), CD8+ T cells ≤ 75 cell/microliter, decreased CD4+ count
- Coagulation Parameters**
 - Prolonged PT
 - Increased fibrin degradation products; D-dimer > 1 microgram/mL
 - Fibrinolysis shutdown (elevated D-Dimer and complete failure of clot lysis at 30 minutes on TEG) predicts thromboembolic events and need for hemodialysis
- Liver/Kidney Biomarkers and Enzymes**
 - High LDH levels
 - Significant elevations in ALT, AST, total bilirubin
 - Significant elevations in BUN and creatinine
 - Elevated C-reactive protein (CRP)
 - Elevated procalcitonin associated with a nearly 5-fold higher risk of severe disease
- Others**
 - Cardiac troponin significantly elevated (WMD: 32.7 ng/L)
 - Acute cardiac injury 13 times more common in ICU-COVID patients than in non-ICU COVID patients
 - Cancer patients - advanced tumor stage, elevated TNF-α and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio
 - Chills, body temperature > 37.5 °C, findings of pneumonia on chest X-ray

POTENTIAL COMPLICATIONS

<p>LUNGS</p> <ul style="list-style-type: none"> ARDS: 15-33% of cases (8 days after sx onset); increased risk in older age, neutrophilia, increased LDH, increased D-Dimer, age >65yrs, DM, HTN Acute respiratory failure: 8% of cases; leading cause of mortality Pneumonia 	<p>THROMBOTIC</p> <ul style="list-style-type: none"> 31% incidence of thrombotic complications in one study of 184 pts Predisposes to venous and arterial thromboembolic events due to excessive inflammation, hypoxia, immobilization and DIC PE is most frequent thrombotic complication Age and coagulopathy (PT>3s, APTT>5s) are independent predictors
<p>CARDIO-VASCULAR</p> <ul style="list-style-type: none"> Reported in 7-20% of cases. Prevalence high among patients who are severely ill Vascular inflammation cardiac arrhythmias, myocarditis, cardiomyopathy, acute onset heart failure, MI, cardiac arrest Less common: myocarditis, cardiac tamponade, fulminant myocarditis 1 case of ITP 	<p>KIDNEY</p> <ul style="list-style-type: none"> Low prevalence, but is a marker of multi organ failure and severe disease 40% pts with proteinuria and 26% with hematuria on admission 5% pts developed AKI and increased hospital mortality Stage 3 AKI in 50% of pts; rhabdomyolysis, metabolic acidosis, and hyperkalemia Old age, DM, severe illness, and positive fluid balance are associated factors
<p>LIVER</p> <ul style="list-style-type: none"> Reported in 14-53% of cases Abnormal aminotransferase levels in patients with severe illness (AST and ALT >40) Clinically significant liver injury is uncommon 	<p>NEUROLOGIC</p> <ul style="list-style-type: none"> Viral invasion of CNS in patients with severe illness Observed in 36% of 214 patients in one study Acute CVA disease, impairment of consciousness, ataxia, seizures, and encephalopathy; prognosis is poor for these patients Guillain-Barre syndrome seen in 4 cases
<p>INFECTION</p> <ul style="list-style-type: none"> Sepsis and septic shock reported in 4-8% of cases Secondary infection reported in 6-10% of cases; staph and strep are common DIC: cytokine release syndrome with persistent fevers, increased ferritin, D-dimer, and proinflammatory cytokines Conjunctivitis seen in several cases 	<p>PREGNANCY</p> <ul style="list-style-type: none"> Incidence of preterm birth, low birth weight, C-section, NICU admission are higher than the general population Maternal death, pregnancy loss, and laboratory evidence of vertical transmission are infrequently reported Most common symptoms are fever (62.9%) and cough (36.8%)
<p>CUTANEOUS</p> <ul style="list-style-type: none"> Exanthematous rash in several cases at disease onset or after recovery "COVID toes" - pernio acral lesions reported across age spectrum Retiform purpura and necrotic vascular lesions with severe cases Vesicular varicella-like eruptions in several reports Multisystem inflammatory syndrome in children (Kawasaki-like) 	<p>LINGERING SYMPTOMS</p> <ul style="list-style-type: none"> Reported cases of persistent loss of smell despite clinical resolution Long-term impaired respiratory functions in some patients who had developed ARDS Potentially increased likelihood for developing cognitive decline after infection

For details and references please visit <https://oume.uthscsa.edu/longco/>